<DOC>
	<DOCNO>NCT01985191</DOCNO>
	<brief_summary>Primary Objectives : To determine recommended Phase 2 dose SAR405838 / pimasertib combination therapy patient solid tumor . To assess anti-tumor activity SAR405838 / pimasertib patient solid tumor . Secondary Objectives : To characterize pharmacokinetic profile SAR405838 pimasertib . To evaluate pharmacodynamic effect SAR405838 pimasertib . To characterize genetic status tumor tissue circulate tumor DNA .</brief_summary>
	<brief_title>A Safety Efficacy Study SAR405838 Pimasertib Cancer Patients</brief_title>
	<detailed_description>The duration study individual patient include period assess eligibility 4 week , treatment period least 6 week study treatment , end-of-study visit least 30 day ( patient receive another anti-cancer therapy , whichever short ) follow last administration study drug .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm diagnosis solid tumor . Presence locally advance metastatic disease least one measurable lesion . Ability provide write informed consent . Evidence personally sign informed consent . Exclusion criterion : Age &lt; 18 year . Eastern Cooperative Oncology Group performance status &gt; 1 . Inadequate function bone marrow , liver , kidney . Positive pregnancy test woman childbearing potential . Pregnancy breastfeed . Extensive prior radiotherapy . The patient retinal degenerative disease , history uveitis , history retinal vein occlusion , history retinal detachment , medically relevant abnormality identify screen ophthalmologic examination . Prior history myositis rhabdomyolysis . Recent major surgery trauma , unhealing/open wound . The patient congestive heart failure , unstable angina , myocardial infarction , cardiac conduction abnormality pacemaker stroke within 3 month enter study . The patient baseline correct QT interval ( QTc ) &gt; 480 m leave ventricular ejection fraction ( LVEF ) &lt; 50 % less low limit normal . The patient previouslyidentified allergy hypersensitivity component study treatment formulation . Unwillingness inability comply schedule visit , drug administration plan , laboratory test , study procedure , study restriction . Unwillingness , postmenopausal surgically sterile , abstain sexual intercourse employ effective barrier medical method contraception study drug administration followup period . Recent history acute pancreatitis . Clinically significant illness , medical condition , surgical history , physical finding , laboratory abnormality could affect safety patient ; alter absorption study drug ; impair assessment study result . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>